quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 23, 2026

Earnings live: Intel stock plunges, with more Big Tech earnings from Apple, Microsoft, and Tesla ahead

View original at finance.yahoo.com
Earnings live: Intel stock plunges, with more Big Tech earnings from Apple, Microsoft, and Tesla ahead The fourth quarter earnings season kicks into high gear in the week ahead, with Big Tech results from Microsoft (MSFT), Meta (META), Tesla (TSLA), and Apple (AAPL) headlining the earnings calendar…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • National security business continues to see good growth and prospects, and civil business is starting to reignite. The market feels like it's at an inflection point.

    80% confidence
  • Seeing sales growth in categories in US and Europe, albeit at a slower pace. Consumer is choosing to be more diligent in using pantry inventory and dosing products more carefully. None of this is untypical and won't sustain. Categories will return to 3-4% growth over time.

    80% confidence
  • Consumers, especially low- to middle-income households, continue to make more frequent trips to the store while purchasing fewer units per trip, a trend that started early in the year and accelerated through Q4

    80% confidence
  • Global inventories of copper on exchanges have risen in recent months during a period of sharp increases in copper prices. Most analysts project the market will be tightly balanced during 2026 with some projecting deficits and others small surpluses.

    80% confidence
  • Our fourth quarter and full year results reflect solid top line growth and strong and stable credit performance. Years of strategic preparation and our choices to consistently invest to sustain long-term growth and returns enable our results and put us in a strong position going forward.

    80% confidence
  • While anticipated some moderation in client trading activity towards back end of year, instead saw acceleration in activity, which contributed to higher volume-related costs including performance-based compensation

    80% confidence
  • The K-shaped economy powers trade-down in basics but trade-up within the more discretionary Beauty sub-sector

    80% confidence
  • Wall Street analysts estimate 8.2% increase in EPS for Q4 2025 for S&P 500. If that rate holds, it would represent the 10th consecutive quarter of annual earnings growth.

    80% confidence
  • Grasberg mine closure impacted copper volumes by 10% for 2025 compared to forecasts

    80% confidence
  • The environment across key markets is marked by volatility and continued pressure from inflation, geopolitical and trade uncertainty, threat of rising unemployment, and overall consumer confidence remains low

    80% confidence
  • The company saw improvement in demand profile across every segment of the business, with premium and loyalty as biggest drivers, and positive trends in Main Cabin

    80% confidence
  • Doesn't see any real hurdles to resuming Grasberg mine operations as planned in Q2 2026

    80% confidence
  • The continued top-line strength for the core consumer segment is still a key differentiator for McCormick

    80% confidence
  • Company has confidence in plans to deliver stronger results in second half of fiscal year. Remains committed to integrated growth strategy and opportunity to reinvent P&G as the CPG company of the future.

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Earnings live: Intel stock plunges, with more Big Tech earnings from Apple, Microsoft, and Tesla ahead — Source | Via News | pt.VIA.NEWS